---
title: "Lionco: Subsidiary Lionco Pharmaceutical's product, injectable cefazolin sodium, is expected to be selected for national centralized drug procurement"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/263233220.md"
description: "Lionco announced that its wholly-owned subsidiary Lionco Pharmaceutical's injectable cefazolin sodium product is expected to be selected for the national centralized drug procurement, with an estimated sales revenue of 23.0089 million yuan in 2024, accounting for 6.06% of the company's annual operating income. If the contract is successfully signed, it will help expand the market and enhance brand influence, but there is uncertainty regarding the subsequent contract signing. The company will closely monitor the progress and fulfill its information disclosure obligations"
datetime: "2025-10-29T07:58:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263233220.md)
  - [en](https://longbridge.com/en/news/263233220.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263233220.md)
generator: "portal-rs"
---

# Lionco: Subsidiary Lionco Pharmaceutical's product, injectable cefazolin sodium, is expected to be selected for national centralized drug procurement

Lionco announced that its wholly-owned subsidiary, Lionco Pharmaceutical, participated in the 11th national centralized procurement organized by the National Organization for Drug Procurement Office, and its product, injectable cefazolin sodium, is expected to be selected. The sales revenue of this product in 2024 is projected to be 23.0089 million yuan, accounting for 6.06% of the company's operating income for 2024. If selected and a purchase and sales contract is signed and implemented, it will promote the market expansion of the company's related products and enhance brand influence, positively impacting future performance. However, there is currently uncertainty regarding the signing of contracts and other follow-up matters, and the company will closely monitor progress and fulfill its information disclosure obligations

### Related Stocks

- [603669.CN](https://longbridge.com/en/quote/603669.CN.md)

## Related News & Research

- [Promise Analyzes Telehealth Licensing Rules as Compact Hits Record 3,633 Licenses in a Month](https://longbridge.com/en/news/296635882.md)
- [HENGRUI PHARMA  1H26 Net Profit Rises 0.3% YoY to RMB4.465 Billion; Shares Now Down Over 7%](https://longbridge.com/en/news/296422700.md)
- [US health agencies report 55 cases of E. coli and salmonella infections tied to alfalfa sprouts](https://longbridge.com/en/news/296645342.md)
- [CDC lifts beneficial stake in Exosens to 11.71% of capital, 13.87% of voting rights](https://longbridge.com/en/news/296499698.md)
- [CANSINOBIO  Tetanus Vaccine New Drug Application Approved](https://longbridge.com/en/news/296498620.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**